Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- PRLD
- Price
- 2.21
- Stock movement down
- -0.17 (-5.86%)
- Company name
- Prelude Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 136.54M
- Ent value
- 125.23M
- Price/Sales
- 13.00
- Price/Book
- 2.33
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 14.33%
- 1 year return (CAGR)
- 123.77%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-05
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
PRLD does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 13.00 |
| Price to Book | 2.33 |
| EV to Sales | 11.93 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 50.02M |
| EPS (TTM) | -1.47 |
| FCF per share (TTM) | -1.32 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 10.50M |
| Gross profit (TTM) | 9.21M |
| Operating income (TTM) | -121.05M |
| Net income (TTM) | -111.77M |
| EPS (TTM) | -1.47 |
| EPS (1y forward) | -1.15 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 87.69% |
| Operating margin (TTM) | -1152.85% |
| Profit margin (TTM) | -1064.50% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 47.53M |
| Net receivables | 0.00 |
| Total current assets | 58.33M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 33.08M |
| Total assets | 94.75M |
| Accounts payable | 2.53M |
| Short/Current long term debt | 17.85M |
| Total current liabilities | 18.19M |
| Total liabilities | 36.22M |
| Shareholder's equity | 58.53M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -100.17M |
| Capital expenditures (TTM) | 120.00K |
| Free cash flow (TTM) | -100.28M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -190.95% |
| Return on Assets | -117.96% |
| Return on Invested Capital | -182.45% |
| Cash Return on Invested Capital | -163.70% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.90 |
| Daily high | 2.90 |
| Daily low | 2.60 |
| Daily Volume | 361K |
| All-time high | 91.68 |
| 1y analyst estimate | 4.00 |
| Beta | 1.06 |
| EPS (TTM) | -1.47 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 18 Mar 2026 |
Downside potential
Loading...
Downside potential data
| PRLD | S&P500 | |
| Current price drop from All-time high | -97.59% | -0.89% |
| Highest price drop | -99.33% | -19.00% |
| Date of highest drop | 8 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -98.74% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 309 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
136.54M
Marketcap category
Small-cap
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Employees
131
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page